Ictal Quality Parameters in ECT



Alexander Sartorius

Head of ECT Research and Supervison Head, Research Group Translational Imaging Department of Psychiatry and Psychotherapy Central Institute of Mental Health (CIMH) Medical Faculty Mannheim University of Heidelberg

www.zi-mannheim.de



Central Institute of Mental Health (CIMH)





Age, intial HAMD, stimulation dosis, "depth of narcosis" ??? concurrent drugs ???

prediction

ictales EEG "adequacy"

prediction



prediction

ECT – anesthesia:

- thiopental
- methohexital
- etomidate
- propofol



0.15-0.3 mg/kg 1-2 mg/kg





German guidelines for tx of status epilepticus

- => lorazepam up to 10mg i.v.
- => phenytoin up to 30 mg/kg KG i.v.
- => phenobarbital 20 mg/kg KG i.v.
- => thiopental **4-7 mg/kg** KG i.v.
- vs. propofol **1-2 mg/kg** KG i.v.
- vs. midazolam or valproate

Dosing of ECT anesthetics



- experience of the anesthesiologist
- experience of previos ECT sessions
 - time needed for full recovery
 - patient remembers muscle relaxation
 - systematic / non-systematic movements of the "cuffed" limb
- objective criteria for
 - "dosing" and "timing"
 - do not exist ...



Bispectral Index Monitoring (BIS)

- has been developed to prevent intraoperative awareness

 uses combined EEG/EMG to derive a measure for "cortical integrity" inter alia by analyzing coherences between different frequency bands

- More precisely: bispectrum is a 3rd order Fourier transformation that includes amplitude, phase AND coherence information. BIS is a normalized index function of the bispectrum.

0-electrically silent brain100-fully vigilant patient

Bispectral Index Monitoring (BIS)



- BIS more **valid** regarding "hypnosis" compared with other algorithms like spectral edge frequency (SEF), median frequency (MF), or delta, theta, alpha, beta power



Liu J, Singh H, White PF (1996) Anesthesiology 84:64-69 Schmidt GN, Bischoff P, et al. (2005) Anaesthesia 60:228-234







Lowest level: **YES**! n= 48, p = 0.04, r = 0.29

Later:

No!

A. Sartorius et al., Br J Anaesth. 2006.A. Sartorius et al., Pharmacopsychiatry. 2006.



CIMH first study on depth of anesthesia

- 22 MDE patients
- 51 ±14 y
- 64 % remitter, 23% responder
- initial
 HAMD₂₁ = 27.7 ± 9

 final
 HAMD₂₁ = 8.5 ± 5
- number of ECT sessions = 10 ± 3 (min 5, max 14) - mean applied "energy" = 40 ± 20 %

200

CIMH first study on depth of anesthesia



A. Sartorius et al., ECT anesthesia: the lighter the better? Pharmacopsychiatry. 2006 Nov;39(6):201-4.

The NEW ENGLAND JOURNAL of MEDICINE

CLINICAL THERAPEUTICS

Electroconvulsive Therapy for Depression

Sarah H. Lisanby, M.D.

N ENGLJ MED 357;19 WWW.NEJM.ORG NOVEMBER 8, 2007

Correspondence:

- 1. Dettling / Anghelescu / Bajbouj
- 2. Guevara-Cuellar / Pineda-Cañar

Reply of S. Lisanby:

Sartorius et al.: "concomitant medications were not controlled"



Age, intial HAMD, stimulation dosis, "depth of narcosis" ??? concurrent drugs ???

prediction

prediction

mean concurrent medication

individual concurrent medication

ictales EEG "adequacy"

prediction

remission



- 41 patients with MDE (totalling in 411 ECTs)
- 99 different drugs in 24h time window before individual ECT
- 25 of those have been either
 - benzodiazepines
 - antidepressants or
 - antipsychotics



Table 3: Mean equivalence doses

		mean (mean of substance positive ECT sessions					
	last 24	h/bw	last 2	24 h			last 24 h	
equivalent of	mean	sd	mean	sd	n	mean	sd	n
diazepam (mg)	0.13	0.15	8.3	9.7	411	11.3	9.7	300
amitriptyline (mg)	0.80	1.3	58	101	411	166	106	144
chlorpromazine (mg)	0.63	1.9	49	158	411	274	283	73

Table 2: Patient characteristics

	remitter (n=19)		responder (n=12)		non-responder (n=10)		anova P	all (n=41)	
	mean	sd	mean	sd	mean	sd		mean	sd
age (y)	56	15	51	18	60	16	0.39	55	16
body weight (kg)	67	12	71	15	67	22	0.73	68	16
initial HAMD	26	7	31	5	25	6	0.05	27	6
final HAMD	5	2	12	2	17	4	< 0.0001	10	6
thiopental (mg/kg bw)*	4.1	1.8	4.3	1.0	3.6	0.9	0.47	4.0	1.4
total # of ECTs	10	4	10	4	10	3	0.99	10	4
at first ECT treatment:									
stimulation energy (%)	21	23	15	7	20	16	0.69	19	18
diazepam equivalent (mg/d)	7.6	6.1	13	11	8.8	7.8	0.22	9.6	8.4
amitriptyline equivalent (mg/d)	74	107	85	150	103	128	0.84	84	123
chlorpromazine equivalent (mg/d)	32	69	83	218	259	456	0.08	102	266

Response was defined as an Hamilton Depression Scale (HAMD₂₁) reduction of at least 50% compared to the value at onset. Remission was defined as a final HAMD₂₁ \leq 8. Initial HAMD scores were taken before first ECT session, final HAMD scores during the week after the last ECT session.



some established markers of "seizure adequacy":

- seizure concordance
- postictal suppression index
- seizure energy index
- motor response time
- duration of EEG seizure activity
- peak heart rate
- midictal amplitude
- total seizure coherence



ictal markers of "seizure adequacy" are not independent from each other:

- seizure concordance
- postictal suppression index
- seizure energy index
- motor response time
- duration of EEG seizure activity
- peak heart rate
- midictal amplitude
- total seizure coherence



200

ictal markers of "seizure adequacy" are not independent from each other:

- seizure concordance = motor response time / duration of EEG seizure activity
- postictal suppression index
- seizure energy index
- motor response time
- duration of EEG seizure activity
- peak heart rate
- midictal amplitude
- total seizure coherence



200

ictal markers of "seizure adequacy":

We identified 5 possibly independent groups:

1. duration:

- EEG determined seizure duration
- motor response time
- 2. amplitude:
 - midictal amplitude
 - seizure energy index
- 3. central inhibition:
 - post-ictal suppression index
 - seizure concordance
- 4. coherence:
 - seizure coherence
- 5. sympathetic activation:
 - maximal post-stimulation heart rate

		independent variables benzo- energy BIS age HAMD, thiopental diazepines AP AD															
											A						
dependent variables	14	CC.	р	cċ	p	cc	р	cc	p	cc	p	cc	P	cc	p	cc	p
EEG seizure duration	0.19	17	0.001	22	0.001	18	0.13	.29	0.33	78	0.58	- 20	0.12	.00	0.72	- 02	0.08
motor response time	0.43	17	0.001	21	0.001	- 25	0.002	.41	0.03	41	0.66	- 08	0.34	.00	0.61	- 00	0.94
midictal amplitude	0.26	29	0.05	.26	0.32	-2.02	0.001	.73	0.46	1.68	0.75	.15	0.76	02	0.41	01	0.89
seizure energy index	0.26	1.25	0.92	41	0.04	-216	0.001	121	0.29	697	0.16	20	0.64	- 63	0.83	-2.8	0.45
postictal suppression	0.14	12	0.03	23	0.01	21	0.11	11	0.72	.11	0.95	28	0.09	.01	0.55	- 01	0.57
concordance	0.33	002	0.001	.002	0.001	- 003	0.004	.004	0.07	.00	0.97	- 00	0.36	.00	0.68	.0002	0.03
ictal coherence	0.14	-,08	0.05	.18	0.02	- 36	0.004	- 09	0.77	2.64	0.09	.02	0.90	.01	0.26	02	0.14
maximal heart rate	0.20	02	0.67	22	0.008	- 68	0.001	.28	0.45	-2.5	0.15	- 20	0.21	01	0.20	+.01	0.48

Table 1: Influence of concurrent drugs on seizure adequacy

The multivariate repeated measurement regression analysis was separately computed for every dependent variable including all independent variables. All dependent variables were quantified by the Thymatron ECT device.

Significant results are shown in **bold italic** letters, results, which are statistically significant after correction for multiple testing are shown in **underlined bold** letters. Bonferroni correction was set at $\alpha = 0.05/8 = 0.00625$. Concordance is the ratio of motor response time and EEG seizure duration and a marker of the central inhibition power.

cc = correlation coefficient, r^2 = explained variance

energy = ECT stimulation energy, BIS = depth of induced narcosis (quantified as bispectral index or BIS) HAMDi = initial severeness of depressive episode (quantified as Hamilton depression 21 item scale)

Conclusion:



concurrent psychotropic medications at typical doses do not interfere with ECT

- at least at a level of ictal parameters predictive for ECT response

Some replications of old findings:





200

 $r^2 = 0.32$

Some replications of old findings:





Frey R, Heiden A, Scharfetter J, Schreinzer D, Blasbichler T, Tauscher J, Felleiter P, Kasper S. J ECT. 2001 Jun;17(2):102-8.



Concordance and antidepressive medication



Seizure concordance and equivalence dosage of amitriptyline [mg / 24h] correlates positively (Pearson: t= 4.02, p< 0.001, r^2 = 0.10, n = 141). In other words: Higher doses of antidepressants led to a better central inhibition of a seizure predicting better outcome.



Post-ictal suppression and antipsychotics



Analyzing post hoc only patients who received antipsychotics led to a significant correlation of postictal suppression and chlorpromazine equivalent dosis (Pearson: $r^2 = 0.18$, t = 3.25, p = 0.002).

Back to anesthetics:



Why we don't use an anesthetic without anticonvulsive properties ?



E. M. Muñoz-Canales¹ B. Krumm² A. Krier^{3,4} F. J. Andres⁴ H.-J. Bender⁴ F. A. Henn¹

A. Sartorius

ECT Anesthesia: The Lighter the Better?





ECT and ketamine



pros:

- **1. Ketamine probably posseses a unique intrinsic antidepressive potential**
- 2. Ketamine has no anticonvulsive action
- 3. Ketamine may posses neuroprotective properties as an NMDA-antagonist
- 4. Ketamine is comparable with amantadine and memantine, which are used as 2nd / 3rd line therapy in catatonia.

cons:

- 1. Ketamine acts non-depressively on the cardio-vascular systeme (like e.g. barbiturates)
- 2. Ketamine dose-dependently induces psychiatric side-effects (basically derealisation and depersonalisation, which can lead to anxiety)

ORIGINAL ARTICLE

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

ORIGINAL ARTICLE

Carlos A. Zarate, Jr, MD; Jasharan B. Singh, MD; Paul J. Carlson, MD; Nancy E. Brutsche, MSN; Rezvan Ameli, PhD; David A. Luchenbaugh, MA; Dennis S. Charney, MD; Husseini K. Manji, MD, FRCPC

Arch Gen Psychiatry 2006

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Nancy Diazgranados, MD, MS; Lobna Ibrahim, MD; Nancy E. Brutsche, MSN; Andrew Newberg, MD; Phillip Kronstein, MD; Sami Khalife, MD; William A. Kammerer, MD; Zenaide Quezado, MD; David A. Luchenbaugh, MA; Giacomo Salvadore, MD; Rodrigo Machado-Vieira, MD, PhD; Husseini K. Manji, MD, FRCPC; Carlos A. Zarate Jr, MD

Arch Gen Psychiatry 2010

ketamine racemate 0.5 mg/kg bw i.v. over 40 mins

dose-effect relation





Glue et al., Biol Psychiatry, 2011

ketamine racemate in mg/kg bw i.m. as bolus

Eur Arch Psychiatry Clin Neurosci DOI 10.1007/s00406-011-0205-7

ORIGINAL PAPER

Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study

Laura Kranaster · Jutta Kammerer-Ciernioch · Carolin Hoyer · Alexander Sartorius





Fig. 3 Differences of the MMSE score before and after ECT of each individual patient in the ketamine (1.2, SD: 1.3, N = 9) and thiopental (-0.5, SD: 2.1, N = 12) group (P = 0.025, one sided) demonstrate a better cognitive outcome after ECT in the ketamine group







Fig. 2 Final HAM-D₂₁ score after ECT of each individual patient in the ketamine (3.6, SD: 1.8, N = 5) and thiopental (9.7, SD: 5.6, N = 14) group (P = 0.015, one sided) indicate a better antidepressant response in the ketamine group

Fig. 5 Individual concordance (ratio of motor response time over EEG seizure duration) of each seizure in the ketamine (0.64, SD: 0.15, N = 174) and thiopental (0.61, SD: 0.21, N = 315) group (P = 0.045, one sided). Ketamine enhances the concordance and thus seizure quality

	Ketamine	Thiopental	P (one sided)
N total	176	321	-
S-ketamine (mg)	46.7 (N = 173) (SD 12.0)	-	<u></u>
Thiopental (mg)	-	236.0 (N = 320) (SD 64.3)	-
Stimulation dose (%)	36.9 (N = 175) (SD 28.6)	39.5 (N = 320) (SD 27.9)	NS
Unilateral stimulation (%)	73 (N = 175) (SD 45)	82 (SD 39)	NS (0.7139)
Seizure duration (motor) (s)	31.1 (N = 175) (SD 23.6)	29.8 (N = 315) (SD 14.1)	NS
Seizure duration (EEG) (s)	49.5 (N = 174) (SD 17.7)	50.2 (N = 317) (SD 22.8)	NS
Concordance	0.64 (N = 174) (SD 0.15)	0.61 (N = 315) (SD 0.21)	0.045
Urapidil (mg)	9.5 (SD 13.1)	6.9 (SD 10.5)	0.030

Table 3 Seizure data of both groups

Presented as means with standard deviation (SD)

NS not significant



PAIN MANAGEMENT/CONCEPTS

Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update

Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM

From the Department of Emergency Medicine, Loma Linda University Medical Center and Children's Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children's Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children's Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krausa).

Contraindications: Absolute (Risks Essentially Always Outweigh Benefits)

- Age younger than 3 months (higher risk of airway complications)
- Known or suspected schizophrenia, even if currently stable or controlled with medications (can exacerbate condition)

Preliminary evaluation of clinical outcome and safety of ketamine as an anesthetic for electroconvulsive therapy in schizophrenia. Kranaster L, Hoyer C, Janke C, Sartorius A. World J Biol Psychiatry. 2012 Mar 8. [Epub ahead of print]

Caseo	#10	#20	#30	#40	#5 - D	#60
Type¤	paranoid□	catatonia□	paranoid¤	paranoida	paranoido	paranoid¤
Sexu	maleo	male¤	female□	maleo	female	maleo
Ageo	530	25¤	65¤	260	47□	570
No. ECT =	340	52*a	310	150	110	50
BMID	9 <u>1</u>	190	220	92	200	270
Duration of Illness (in- years)=	380	% <u>.</u> \$¤	340	0.5%	1.0°0	149
Psychotrophic medication duringECT treatment©	Haloperidol, Lorazepam ³	Clozapine, Risperidone, Lorazepam, Escitalopramo	Olanzapine, Venlafaxine¤	Risperidone, Lorazepamo	Aripiprazole	Olanzapine, Amisulpride, Mirtazapine®
Outcomed	Remission©	Response	No responsed	Remission	Response	Remission©

Table 1: The demographic data of the patients with schizophrenia, who received ketamine as-

narcotic for ECT. (*including maintenance ECT)

Conclusions:



1.It 's worth controlling for depth of anesthesia (BIS-monitoring)

2.It 's worth looking for ictal parameters (predicting session adequacy)

3.It 's worth keeping alternatives in mind (ketamine)

4.It 's probably not worth to limit concurrent drugs (at least at typical doses and due to ictal parameters)

Acknowledgement:



Central Institute of Mental Health (CIMH), Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Ruprecht Karls University Heidelberg Fritz A. Henn

A. Meyer-Lindenberg Walter Hewer Eva-Maria Munoz-Canales Bogata D. Bundy Jutta Kammerer Laura Kranaster Carolin Hoyer

Department of Anaesthesiology and Intensive Care Medicine, Medical Faculty Mannheim, Ruprecht Karls University Heidelberg

Franz-Josef Andres Andreas Krier Christoph Janke

